AstriVax Begins Clinical Trials for Innovative Vaccine Platform Technology

Overview

AstriVax has commenced a Phase I clinical study to assess the safety and effectiveness of its prophylactic vaccines for yellow fever (AVX70120) and rabies (AVX70481) in healthy adults. This initial human trial, called SAFYR, aims to provide essential safety and immunogenicity data, which will be crucial for advancing AstriVax's therapies for chronic infections such as Hepatitis B and human papillomavirus (HPV).

SAFYR Study in Belgium

The SAFYR study is being conducted at two leading vaccine trial sites in Belgium: the Centre for Vaccinology in Ghent and Vaccinopolis in Antwerp. The trial will involve nearly 100 healthy adults aged 18 to 40 to assess the safety and immune response generated by these vaccines. The results are expected to offer clinical validation for the AstriVax vaccine platform.

From AstriVax

AstriVax, noted, “This trial showcases our innovative technology in a clinical proof-of-concept study. We use plasmids to deliver live-attenuated virus vectors with the target viral antigen, creating a self-amplifying mechanism that aims to produce strong and lasting immune responses with minimal doses.”

AstriVax's Revolutionary Vaccines

• AstriVax's groundbreaking vaccines are expected to transform the fight against viral pathogens. 
• They are designed for easy production, have minimal cold chain requirements, and are anticipated to trigger robust, long-lasting immune responses.

About AstriVax

Currently, AstriVax is a clinical-stage company with a strong pipeline targeting viral infections and addressing urgent medical needs, such as chronic Hepatitis B, which affects over 250 million people, and HPV, a major cause of cervical cancer.

AstriVax, reflected, “Less than two years ago, we started with strong academic foundations and secured a €30 million seed round. In May 2023, we received a grant from Flanders Innovation & Entrepreneurship (VLAIO) to further advance our technology. I am incredibly grateful to my exceptional team for their dedication in shaping the company. We expect our chronic Hepatitis B immunotherapy to enter the clinical phase in 2025, marking another significant milestone for AstriVax.”

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!